[Rotigotine for Parkinson’s disease]
Soto N, García Martí S, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001439
Spanish
Original Title:
Rotigotina en enfermedad de Parkinson
Authors' recommendations:
CONCLUSIONS
High-quality evidence suggests that rotigotine is better than placebo in managing Parkinson’s disease symptoms throughout the disease stages. Moderate-quality evidence suggests its effectiveness is comparable to that of other dopaminergic agonists in controlling symptoms and discontinuation rate.
In general, Latin American health sponsors do not cover it. The health sponsors consulted from other countries and the clinical practice guidelines agree on considering it as another option comparable to other available dopaminergic agonists; some restrict its indication for patients to whom oral medication can not be administered or who have shown no response to other options, given its higher cost.
Details
Project Status:
Completed
Year Published:
2018
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Parkinson Disease
- Dopamine Agonists
- Tetrahydronaphthalenes
- Thiophenes
- Drug Therapy
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.